Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term inhaled molgramostim in autoimmune pulmonary alveolar proteinosis
2017-004078-32Phase 3Terminated
- Sponsor
- Savara
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP) and pulmonary alveolar proteinosis (PAP), sponsored by Savara. Primary endpoint: Safety events. Started Dec 2017; status: terminated.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)pulmonary alveolar proteinosis (PAP)
Beyond the preview
Go deeper on 2017-004078-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004078-32.